Shionogi Incis A U Sbased Subsidiary Of The Japanese Pharmaceutical Company Shionogi & Co Ltd Which Has Been A Leader In Drug Development Since Its Founding In 1878The Company Focuses On Creating Innovative Treatments For Infectious Diseasespain Managementhivand Influenzanotable Products Include Antibiotics Like Sulfamethoxazole And Delafloxacinwhich Received Fda Approval In 2017 With A Strong Commitment To Research And Developmentshionogi Allocates Over 15Of Its Annual Revenue To R&Ddriving Advancements In Various Therapeutic Areasthe Company Has Established Significant Partnerships With Major Pharmaceutical Firmsenhancing Its Global Presence And Ability To Serve Healthcare Providers And Patients Worldwideas Of March 2023Shionogi Reported A Revenue Of Approximately Ay420 Billionaround $3 5 Billion Reflecting Its Ongoing Growth In The Pharmaceutical Market
